Metraipolis › archive › dc_95db1f5fa506
A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus… — Europe PMC PMID:41694351
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/41694351
- DOI
- 10.3389/fimmu.2026.1729883
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-06T11:10:20.375Z
- SHA-256 of the archived text
c804c809b78a71de504ae707c29ac94cd1e705f70cf7a147d54d122187282510- Stable URL of this page
https://metraipolis.com/documento/dc_95db1f5fa506
How to cite
A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus… — Europe PMC PMID:41694351 — Europe PMC (en), https://europepmc.org/article/MED/41694351 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_95db1f5fa506 (Metraipolis archive dc_95db1f5fa506, sha256 c804c809b78a71de504ae707c29ac94cd1e705f70cf7a147d54d122187282510)
BibTeX
@misc{dc95db1f5fa506,
title = {A combination of low TMB and PD-L1 expression predict poor progression-free survival of metastatic melanoma patients treated with first-line ipilimumab plus… — Europe PMC PMID:41694351},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/41694351},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_95db1f5fa506; sha256 c804c809b78a71de504ae707c29ac94cd1e705f70cf7a147d54d122187282510},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41694351. Agents can read the archived copy with the MCP tool read_document.